Sep 19, 2017
RXi Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
Sep 18, 2017
RXi Pharmaceuticals to Present at BioPharm America's 10th Annual International Partnering Conference
Sep 15, 2017
RXi Pharmaceuticals Announces the Departure of Dr. Alexey Eliseev as Chief Business Officer
Sep 15, 2017
BioAxone BioSciences Awarded NINDS SBIR Funding for the Development of Self-Delivering RNAi (sd-rxRNA®) for the Treatment of Spinal Cord Injury
Sep 06, 2017
RXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts
Aug 31, 2017
RXi Pharmaceuticals Corporation Selected to Present at the 8th Annual Investing for Cures Forum
Aug 10, 2017
RXi Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
Aug 09, 2017
RXi Pharmaceuticals Enters into Common Stock Purchase Agreement for Up to $15.0 Million
Aug 08, 2017
RXi Pharmaceuticals Advances Immuno-Oncology Pipeline by Selecting Two sd-rxRNA Compounds for Preclinical Development and Sourcing cGMP Manufacturing
Aug 04, 2017
How These Biotech Stocks are Performing? -- Agenus, Aptose Biosciences, RXi Pharma, and Tenax Therapeutics
Aug 03, 2017
RXi Pharmaceuticals Granted 180-Day Extension by Nasdaq Stock Market to Regain Compliance with Listing Requirements
Jun 21, 2017
RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring
Jun 12, 2017
RXi Pharmaceuticals Announces the Initiation of its Consumer Testing Program with RXI-231
Jun 08, 2017
RXi Pharmaceuticals to Present at the Marcum MicroCap Conference
Jun 07, 2017
RXi Pharmaceuticals Corporation Announces the Appointment of Dr. Jonathan Freeman to its Board of Directors